WE ARE TARGETING PAIN AT ITS SOURCE
Our novel drug compounds, improved drug-delivery systems, and drug-releasing technologies are focused on advancing pain management treatments allowing healthcare professionals to target a patient’s pain at its source. Our products cover a range of applications from the postoperative pain to the treatment of acute and chronic pain.
Transdermal metered-dose spray
Virpax has licensed a patented aerosol-based system that delivers active pharmaceutical ingredients (API) as a Patch-in-a-Can. This proprietary spray formulation delivers the API as a film and can be manipulated to deliver API immediately or over an extended time from 12 to 24 hours.
CONVENIENT
No messy cream or gels that can be rubbed off by clothing or physical contact
AESTHETICALLY APPEALING
Invisible once applied
EASILY OPTIMIZABLE
Use with metered-dose delivery valves
“I feel that a large number of pain patients will prefer the spray over patches and ointment and am really glad to see this new technology that will allow more precise application while using lesser active ingredient.”
SANJAY GUPTA
President, American Pain Association
Liposomal in Hydrogel encapsulation
Our patented liposomal gel encapsulates a high dose of local anesthetic in hydrogel, cholesterol, and other “GRAS” lipids. A single dose can be injected at the surgical site to provide a prolonged postoperative analgesia effect for up to 96 hours. This may enhance recovery protocols, reduce the length of a patient’s hospital stay post-surgery, and significantly reduce or eliminate the use of opioids.
PROLONGED EFFECTS
Postoperative analgesia effect for up to 96 hours
EFFICIENT DRUG-DELIVERY
Fast onset of action and peak analgesic activity in post-operative setting
IMPROVED QUALITY OF CARE
Reduce reliance on opioid pain management; may lead to experience better rehabilitation outcomes
Intranasal spray
Using Molecular Envelope Technology (MET), we are working to enhance enkephalin transport to the brain through an intranasal formulation. This nanotechnology enables metabolically labile peptide molecules, like enkephalin, to pass through the blood-brain barrier in order to help manage chronic pain. These enkephalin-filled nanoparticles are preloaded into a cartridge with compressed inert gas as a single dose that is compatible with our specialized device. With a simple press of a button, the device releases this powder as a long and thin plume penetrating the olfactory region.
DRUG LOADED NANOPARTICLES
The enkephalin molecule is loaded in nanoparticles
EASY-TO-USE DEVICE
No breath coordination required. Caregiver can administer to an incapacitated person
BLOOD-BRAIN BARRIER BYPASS
Drug bypasses the blood brain barrier by targeting the olfactory region
DSF100
Topical NSAID spray film
STATUS: CAPITAL FUNDING
DSF100
Topical NSAID spray film
CAPITAL FUNDING
TARGET MARKET
Topical treatment for acute musculoskeletal pain
DELIVERY SYSTEM
Metered-dose spray film
BENEFITS
- Faster drying, less messy, comparable skin absorption, and improved patient compliance
- Better adhesiveness with direct skin contact
- Better accessibility to active joints: wrists, ankles, knees and elbows
- Improved patient compliance that could result in enhanced therapeutic outcomes
NEW DRUG APPLICATION (NDA)
As a result of our PreIND review, the FDA has indicated that it is reasonable for Virpax to pursue a 505(b)(2) New Drug Application for DSF100.
LBL100
Long-acting local anesthetic/liposomal-gel
STATUS: CAPITAL FUNDING
Probudur™
Long-acting local anesthetic/liposomal-gel
CAPITAL FUNDING
TARGET MARKET
Post surgical knee and hip pain
DELIVERY SYSTEM
Liposomal in hydrogel encapsulation
BENEFITS
- Single dose infiltration into the surgical site
- Prolonged postoperative analgesia effect up to 96 hours
- May eliminate the need for opioids and catheters after surgery
- May reduce associated costs and length of patient stay
- May significantly reduce or eliminate opioids
NEW DRUG APPLICATION (NDA)
As a result of our PreIND review, the FDA has indicated that it is reasonable for Virpax to pursue a 505(b)(2) New Drug Application for LBL100.
RES202
Long-acting naloxone-naltrexone/liposomal-gel
STATUS: GRANT AND RESEARCH
Epoladerm™
Topical NSAID spray film
CAPITAL FUNDING
TARGET MARKET
Topical treatment for chronic osteoarthritis of the knee
DELIVERY SYSTEM
Metered-dose spray film
BENEFITS
- Faster drying and no messy handling
- Better skin absorption for faster onset
- Comparable accessibility to active knees and twice daily dosing
- Improved patient compliance that could result in enhanced therapeutic outcomes
NEW DRUG APPLICATION (NDA)
As a result of our PreIND review, the FDA has indicated that it is reasonable for Virpax to pursue a 505(b)(2) New Drug Application for Epoladerm
NES100
Endogenous enkephalin intranasal spray
STATUS: GRANT
NES100
Endogenous enkephalin intranasal spray
GRANT
TARGET MARKET
Treatment of acute and chronic pain
DELIVERY SYSTEM
Endogenous enkephalin intranasal spray
BENEFITS
- Enkephalin prodrug formulation that targets delta receptors instead of mu receptors that are responsible for the majority of undesirable side effects associated with narcotics
- Analgesic potential to manage chronic pain without the concerns of opioid tolerance, withdrawal, respiratory depression, or euphoria
RES202
Long-acting naloxone-naltrexone/liposomal-gel
STATUS: GRANT AND RESEARCH
RES202
Long-acting doxapram-naloxone/liposomal-gel
GRANT AND RESEARCH
TARGET MARKET
Rapid-onset and long-lasting opioid antagonist
DELIVERY SYSTEM
Intramuscular auto-injection
BENEFITS
- May reverse opioid side effects up to 48 hours
- Rapid and enduring rescue and reversal of opioid overdose
- Intramuscular rescue auto injection is more effective at reversing respiratory depression cause by opioid overdose
